Great Lakes Advisors LLC decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) by 31.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,001 shares of the company’s stock after selling 55,503 shares during the quarter. Great Lakes Advisors LLC’s holdings in Progyny were worth $4,682,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. CWM LLC lifted its position in Progyny by 14.1% in the 1st quarter. CWM LLC now owns 2,909 shares of the company’s stock valued at $93,000 after purchasing an additional 360 shares during the last quarter. Yousif Capital Management LLC increased its stake in shares of Progyny by 1.1% in the first quarter. Yousif Capital Management LLC now owns 37,264 shares of the company’s stock valued at $1,915,000 after purchasing an additional 392 shares during the period. First Republic Investment Management Inc. raised its holdings in shares of Progyny by 4.6% during the fourth quarter. First Republic Investment Management Inc. now owns 9,006 shares of the company’s stock valued at $281,000 after buying an additional 395 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Progyny by 25.0% during the first quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after buying an additional 418 shares during the period. Finally, Park Place Capital Corp grew its holdings in Progyny by 48.0% in the 1st quarter. Park Place Capital Corp now owns 1,424 shares of the company’s stock worth $46,000 after buying an additional 462 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.
Analysts Set New Price Targets
Several analysts have weighed in on the company. Canaccord Genuity Group started coverage on Progyny in a research note on Wednesday, September 27th. They set a “buy” rating and a $46.00 target price on the stock. Truist Financial cut their price objective on shares of Progyny from $52.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. JPMorgan Chase & Co. decreased their target price on shares of Progyny from $58.00 to $57.00 and set an “overweight” rating for the company in a research report on Monday, October 9th. Cantor Fitzgerald raised their target price on shares of Progyny from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Finally, KeyCorp reduced their price target on shares of Progyny from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.
Progyny Price Performance
NASDAQ PGNY opened at $33.09 on Tuesday. The company has a market capitalization of $3.17 billion, a P/E ratio of 63.63, a PEG ratio of 1.29 and a beta of 1.53. Progyny, Inc. has a 12 month low of $28.03 and a 12 month high of $44.95. The company’s 50 day simple moving average is $32.65 and its 200 day simple moving average is $36.36.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. Progyny had a return on equity of 11.64% and a net margin of 5.03%. The company had revenue of $280.90 million for the quarter, compared to analysts’ expectations of $271.20 million. During the same quarter in the prior year, the company earned $0.13 earnings per share. The firm’s revenue was up 36.8% on a year-over-year basis. On average, analysts anticipate that Progyny, Inc. will post 0.57 earnings per share for the current year.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Five stocks we like better than Progyny
- ESG Stocks, What Investors Should Know
- Safeguard your portfolio with these three bargain stocks
- Business Services Stocks Investing
- Membership clubs gain leverage for the consumer rebound
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.